AbbVie - M&A Summary and Business Overview

Life ScienceCompany

AbbVie M&A Summary

AbbVie has acquired 10 companies, including 7 in the last 5 years. It has also divested 1 asset.

AbbVie’s largest acquisition to date was in 2019, when it acquired Allergan for $63.0B. It’s largest disclosed sale occurred in 2020, when it sold Rare Pediatric Disease Priority Review Voucher to United Therapeutics for $105M. AbbVie has acquired in 6 different US states, and 3 countries. The Company’s most targeted sectors include life science (100%).

AbbVie Business Overview

Where is AbbVie headquartered?

AbbVie is headquartered in North Chicago, Illinois.

What is AbbVie’s revenue?

AbbVie disclosed revenue of 58,054M USD for 2022 and 56,197M USD for 2021.

How many employees does AbbVie have?

AbbVie has 50,000 employees.

What sector is AbbVie in?

AbbVie is a life science company.

When was AbbVie founded?

AbbVie was founded in 2012.

M&A Summary

  • M&A Total Activity11
    • M&A Buy Activity10
    • M&A Sell Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 1
  • M&A Advisors 8

AbbVie

AbbVie, Inc.

1 North Waukegan Road,
North Chicago, Illinois 60064
United States,
(847) 932-7900
www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (1.0/yr) # 5 - - 2 2 1 10
vol $90.2B $1.0B $18.8B $138M $110.1B
Sell (0.2/yr) # - 1 - - - - 1
vol $105M $105M
  11

Most Recent M&A

Company Date Value Type
Landos Biopharma, Inc. 2024-03-25 138M USD Add-on Acquisition
Blacksburg, Virginia · www.landosbiopharma.com
Cerevel Therapeutics, Inc. 2023-12-06 8.7B USD Add-on Acquisition
Cambridge, Massachusetts · www.cerevel.com
ImmunoGen, Inc. 2023-11-30 10.1B USD Add-on Acquisition
Waltham, Massachusetts · www.immunogen.com
DJS Antibodies Ltd. 2022-10-20 - Add-on Acquisition
Oxford, United Kingdom · www.djsantibodies.com
Syndesi Therapeutics SA 2022-03-01 1.0B USD Add-on Acquisition
Louvain-la-Neuve, Belgium · www.syndesitherapeutics.com
Rare Pediatric Disease Priority Review Voucher (PPRV) 2020-12-28 105M USD Divestiture
, United States
Mavupharma 2019-07-15 - Add-on Acquisition
Kirkland, Washington · www.mavupharma.com
Allergan plc 2019-06-25 63.0B USD Add-on Acquisition
Parsippany, New Jersey · www.allergan.com
Stemcentrx, Inc. 2016-04-28 5.8B USD Add-on Acquisition
South San Francisco, California · www.stemcentrx.com
Rare Pediatric Disease Priority Review Voucher (PPRV) 2015-08-19 350M USD Divestiture
, United States
View All >>

Business Unit M&A

Company Acquired Add-On/Sale Date #
Allergan plc 2019-06-25 Zenpep 2020-01-27 1
Parsippany, New Jersey · www.allergan.com Parsippany, New Jersey · www.zenpep.com

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 10 (100%) 110.1B (100%) 1 (100%) 105M (100%)
Total 10 $110.1B 1 $105M

By Geo

State/Country Buy Value Sell Value
United States 8 109.1B 1 105M
  Massachusetts 2 18.8B - -
  California 2 26.8B - -
  Washington 1 - - -
  Virginia 1 138M - -
  New Jersey 1 63.0B - -
Belgium 1 1.0B - -
United Kingdom 1 - - -
Domestic 8 (80%) 109.1B (99%) 1 (100%) 105M (100%)
Cross-border 2 (20%) 1.0B (1%) - -
Total 10 $110.1B 1 $105M

Top M&A Advisors

Financial Deals
Morgan Stanley
4
J.P. Morgan Securities
1
PJT Partners, Inc.
1
Legal Deals
Kirkland & Ellis
2
Wachtell, Lipton, Rosen & Katz
2
Paul, Weiss, Rifkind, Wharton & Garrison
1

Deal Values

buy # Total
> $1B 6 $109.6B
$100M to $1B 2 $488M
TOTAL $110.1B
Largest Allergan plc
$63.0B (2019-06-25)
sell # Total
$100M to $1B 1 $105M
TOTAL $105M
Largest Rare Pediatric Disease Priority Review Voucher (PPRV)
$105M (2020-12-28)

M&A Connections

Deals
Acquired from
Strategic(s)
10%
1 (10%)
Divested to
Strategic(s)
100%
1 (100%)

 Subscribe to unlock this and 202,679
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.